검색어 : 통합검색[Hilpert Ulrich]
총 45건 중 45건 출력
, 5/5 페이지
-
41
- Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
- Kommoss, Stefan; Winterhoff, Boris; Oberg, Ann L.; Konecny, Gottfried E.; Wang, Chen; Riska, Shaun M.; Fan, Jian-Bing; Maurer, Matthew J.; April, Craig; Shridhar, Viji; Kommoss, Friedrich; du Bois, Andreas; Hilpert, Felix; Mahner, Sven; Baumann, Klaus; Schroeder, Willibald; Burges, Alexander; Canzler, Ulrich; Chien, Jeremy; Embleton, Andrew C.; Parmar, Mahesh; Kaplan, Richard; Perren, Timothy; Hartmann, Lynn C.; Goode, Ellen L.; Dowdy, Sean C.; Pfisterer, Jacobus; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.; Division of Gynecologic Surgery, Mayo Clinic, Minnesota.; Department of Health Sciences Research, Mayo Clinic, Minnesota.; Division of Medical Oncology, UCLA, California.; Department of Health Sciences Research, Mayo Clinic, Minnesota.; Department of Health Sciences Research, Mayo Clinic, Minnesota.; AnchorDx Corporation, Guangzhou, China.; Department of Health Sciences Research, Mayo Clinic, Minnesota.; Illumina Inc., San Diego, California.; Department of Laboratory Medicine, Mayo Clinic, Minnesota.; Institute of Pathology, Mannheim, Germany.; Kliniken Essen Mitte (KEM), Deptartment of Gynecology and GynecologicOncology, Essen, Germany.; Department of Gynecology and Obstetrics, Schleswig-Holstein University, Kiel, Germany.; Department of Obstetrics and Gynecology, Ludwig Maximillian University Munich, Germany.; Department of Gynecology and Gynecologic Oncology, Philipps University Marburg,; (Clinical Cancer research : an official journal of the American Association for Cancer Research, v.23, 2017, pp.3794-3801)
-
42
- Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
-
Fumet, Jean-David;
Lardenois, Emilie;
Ray-Coquard, Isabelle;
Harter, Philipp;
Joly, Florence;
Canzler, Ulrich;
Truntzer, Caroline;
Tredan, Olivier;
Liebrich, Clemens;
Lortholary, Alain;
Pissaloux, Daniel;
Leary, Alexandra;
Pfisterer, Jacobus;
Eeckhoutte, Alexandre;
Hilpert, Felix;
Fabbro, Michel;
Caux, Christophe;
Alexandre, Jé
rô
me;
Houlier, Auré
lie;
Sehouli, Jalid;
Sohier, Emilie;
Kimmig, Rainer;
Dubois, Bertrand;
Spaeth, Dominique;
Treilleux, Isabelle;
Frenel, Jean-Sé
bastien;
Herwig, Uwe;
Le Saux, Olivia;
Bendriss-Vermare, Nathalie;
du Bois, Andreas;
GINECO & Department of Medical Oncology, Center GF Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France;
Cancer Research Center of Lyon, Université
de Lyon, Université
Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Lé
on Bé
rard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France;
emilie.lardenois@lyon.unicancer.fr (E.L.);isabelle.ray-coquard@lyon.unicancer.fr (I.R.-C.);christophe.caux@lyon.unicancer.fr (C.C.);bertrand.dubois@lyon.unicancer.fr (B.D.);olivia.lesaux@lyon.unicancer.fr (O.L.S.); Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Lé on Bé rard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France;emilie.lardenois@lyon.unicancer.fr (E.L.);isabelle.ray-coquard@lyon.unicancer.f; (Cancers, v.14, 2022, pp.1189)
-
43
- Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense?
- Woelber, Linn; Bommert, Mareike; Prieske, Katharina; Fischer, Inger; zu Eulenburg, Christine; Vettorazzi, Eik; Harter, Philipp; Jueckstock, Julia; Hilpert, Felix; de Gregorio, Niko; Iborra, Severine; Sehouli, Jalid; Ignatov, Atanas; Hillemanns, Peter; Fuerst, Sophie; Strauss, Hans-Georg; Baumann, Klaus; Beckmann, Matthias; Mustea, Alexander; Meier, Werner; Wimberger, Pauline; Hanker, Lars; Canzler, Ulrich; Fehm, Tanja; Luyten, Alexander; Hellriegel, Martin; Kosse, Jens; Heiss, Christoph; Hantschmann, Peer; Mallmann, Peter; Tanner, Berno; Pfisterer, Jacobus; Mahner, Sven; Schmalfeldt, Barbara; Jaeger, Anna; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Gynecology and Gynecologic Oncology Kliniken Essen-Mitte, Essen, Germany; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Epidemiology, UMCG, Universitä t Groningen, Groningen, Netherlands; Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Gynecology and Gynecologic Oncology Kliniken Essen-Mitte, Essen, Germany; Department of Gynecology and Obstetrics, University Hospital, LMU-University of Munich, Munich, Germany; Oncologic Medical Center at the Jerusalem Hospital Hamburg, Hamburg, Germany; Department of Obstetrics and Gynecology, University of Ulm Medical Center, Ulm, Germany; Gy; (Geburtshilfe und Frauenheilkunde : Ergebnisse der Forschung für die Praxis, v.80, 2020, pp.1221-1228)
-
44
- Mutual intrusions: Ulrich Seidl's Import/Export through Jean-Luc Nancy
- Hilpert, Stephan; ; (Studies in European cinema, v.9, 2012, pp.53-67)
-
45
- Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
- Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar; Rau, Joern; Mahner, Sven; Pautier, Patricia; El-Balat, Ahmed; Kurtz, Jean-Emmanuel; Canzler, Ulrich; Sehouli, Jalid; Heubner, Martin L.; Hartkopf, Andreas D.; Baumann, Klaus; Hasenburg, Annette; Hanker, Lars C.; Belau, Antje; Schmalfeldt, Barbara; Denschlag, Dominik; Park-Simon, Tjoung-Won; Selle, Fré dé ric; Jackisch, Christian; Burges, Alexander; Lü ck, Hans-Joachim; Emons, Gü nter; Meier, Werner; Gropp-Meier, Martina; Schrö der, Willibald; de Gregorio, Nikolaus; Hilpert, Felix; Harter, Philipp; Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group and Gynecologic Oncology Center, Kiel, Germany; Groupe d’Investigateurs National des Etudes des Cancers Ovariens et du sein (GINECO) and Centre Franç ois Baclesse, University Caen Normandie, Caen, France; Nordic Society of Gynaecological Oncology (NSGO) and Oslo University Hospital, Oslo, Norway; AGO Study Group and Coordinating Center for Clinical Trials, Philipps-University Marburg, Marburg, Germany; AGO Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, Germany; GINECO and Gustave Roussy Cancer Center, Villejuif, France; AGO Study Group and University Hospital Frankfurt, Frankfurt, Germany; GINECO and Institut de Cancé rologie Strasbourg Europe, Strasbourg, France; AGO Study Group and University Hospital Carl Gustav Carus, Technische Universitä t Dresden and National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany; AGO Study Group and Charité -U; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.41, 2023, pp.893-902)
QUICK MENU
